Kymera Therapeutics, Inc. (NASDAQ:KYMR) Short Interest Update

Kymera Therapeutics, Inc. (NASDAQ:KYMR) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 8,810,000 shares, a decrease of 7.2% from the September 15th total of 9,490,000 shares. Based on an average daily trading volume, of 503,400 shares, the days-to-cover ratio is currently 17.5 days.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on KYMR shares. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Morgan Stanley lifted their price target on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a report on Wednesday, August 14th. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Monday, September 9th. Wells Fargo & Company lifted their price target on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. Finally, Oppenheimer lifted their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.00.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total value of $651,780.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. 15.82% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Comerica Bank increased its stake in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after purchasing an additional 400 shares during the period. Public Employees Retirement Association of Colorado bought a new stake in Kymera Therapeutics during the second quarter valued at about $139,000. Quest Partners LLC boosted its position in Kymera Therapeutics by 1,402.0% during the second quarter. Quest Partners LLC now owns 5,212 shares of the company’s stock valued at $156,000 after purchasing an additional 4,865 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock worth $164,000 after acquiring an additional 295 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Kymera Therapeutics in the second quarter worth about $201,000.

Kymera Therapeutics Trading Down 5.7 %

Shares of NASDAQ:KYMR opened at $46.25 on Friday. Kymera Therapeutics has a 12-month low of $9.60 and a 12-month high of $53.27. The company has a market cap of $2.84 billion, a PE ratio of -18.43 and a beta of 2.21. The stock has a 50 day moving average of $46.36 and a 200 day moving average of $39.81.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.10. The business had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.67) EPS. Equities research analysts predict that Kymera Therapeutics will post -2.85 earnings per share for the current fiscal year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.